As of 2024-07-27, the EV/EBITDA ratio of BioCryst Pharmaceuticals Inc (BCRX) is -26.96. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BCRX's latest enterprise value is 2,378.96 mil USD. BCRX's TTM EBITDA according to its financial statements is -88.25 mil USD. Dividing these 2 quantities gives us the above BCRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 23.3x | 20.5x |
| Forward P/E multiples | 21.8x - 25.1x | 24.2x |
| Fair Price | (13.01) - (13.65) | (13.22) |
| Upside | -265.7% - -273.9% | -268.4% |
| Date | EV/EBITDA |
| 2024-07-26 | -26.96 |
| 2024-07-25 | -26.26 |
| 2024-07-24 | -25.91 |
| 2024-07-23 | -26.07 |
| 2024-07-22 | -25.95 |
| 2024-07-19 | -25.30 |
| 2024-07-18 | -25.09 |
| 2024-07-17 | -25.60 |
| 2024-07-16 | -26.44 |
| 2024-07-15 | -25.39 |
| 2024-07-12 | -25.32 |
| 2024-07-11 | -25.06 |
| 2024-07-10 | -23.78 |
| 2024-07-09 | -23.75 |
| 2024-07-08 | -23.61 |
| 2024-07-05 | -23.85 |
| 2024-07-03 | -23.59 |
| 2024-07-02 | -23.92 |
| 2024-07-01 | -24.20 |
| 2024-06-28 | -23.05 |
| 2024-06-27 | -22.89 |
| 2024-06-26 | -23.05 |
| 2024-06-25 | -22.82 |
| 2024-06-24 | -23.26 |
| 2024-06-21 | -23.61 |
| 2024-06-20 | -22.98 |
| 2024-06-18 | -22.63 |
| 2024-06-17 | -23.19 |
| 2024-06-14 | -23.03 |
| 2024-06-13 | -23.17 |
| 2024-06-12 | -23.33 |
| 2024-06-11 | -23.75 |
| 2024-06-10 | -23.85 |
| 2024-06-07 | -23.36 |
| 2024-06-06 | -23.66 |
| 2024-06-05 | -24.48 |
| 2024-06-04 | -24.36 |
| 2024-06-03 | -24.48 |
| 2024-05-31 | -23.71 |
| 2024-05-30 | -23.96 |
| 2024-05-29 | -22.98 |
| 2024-05-28 | -23.08 |
| 2024-05-24 | -22.94 |
| 2024-05-23 | -23.40 |
| 2024-05-22 | -24.17 |
| 2024-05-21 | -23.61 |
| 2024-05-20 | -22.94 |
| 2024-05-17 | -23.29 |
| 2024-05-16 | -23.73 |
| 2024-05-15 | -23.47 |